2m 2m 2m 2m 2m 2m 2m
- $5.8MMarket Cap
- -46.76%1-Year Change
- BiotechnologyIndustry
CARDIO DGNS HLD (CDIO)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 70
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Key Executives
- Meeshanthini Dogan
- Elisa Michael Luqman
- Timur Dogan
- Robert A. Philibert
Current Ownership Distribution
- Mutual Funds5.2M (37.06%)
- Insiders4.8M (33.78%)
- Institutions4.1M (29.16%)
- Other0 (0.00%)